- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01815359
ICARuS Quimioterapia intraperitoneal pós-operatória (EPIC) e quimioterapia intraperitoneal hipertérmica (HIPEC) após cirurgia citorredutora ideal (CRS) para neoplasias do apêndice, cólon ou reto com metástase peritoneal isolada (ICARuS)
ICARuS (quimioterapia intraperitoneal após cirurgia citorredutora): um estudo multicêntrico e randomizado de fase II de quimioterapia intraperitoneal pós-operatória precoce (EPIC) e quimioterapia intraperitoneal hipertérmica (HIPEC) após cirurgia citorredutora ideal (CRS) para neoplasias do apêndice, cólon ou Reto com metástase peritoneal isolada
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Florida
-
Miami, Florida, Estados Unidos
- University of Miami
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Memorial Sloan Kettering Basking Ridge (Consent and Follow up)
-
Middletown, New Jersey, Estados Unidos, 07748
- Memorial Sloan Kettering Monmouth (Consent and Follow up)
-
Montvale, New Jersey, Estados Unidos, 07645
- Memorial Sloan Kettering Bergen (Consent and Follow up)
-
-
New York
-
Commack, New York, Estados Unidos, 11725
- Memorial Sloan Kettering Commack (Consent and Follow up)
-
Harrison, New York, Estados Unidos, 10604
- Memorial Sloan Kettering Westchester (Consent and Follow up)
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Estados Unidos, 11553
- Memorial Sloan Kettering Nassau (Consent and Follow up)
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patient's age 18 years or older, both genders.
- Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis.
- Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
- ECOG performance status ≤ 1.
- Hematology: ANC ≥ 1,500/ μL; Platelets > 75,000/ μL.
- Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50ml/min.
- Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).
- Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
- A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study.
- Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
- Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated.
Exclusion Criteria:
- Subjects who have previously undergone intraperitoneal chemotherapy.
- Subjects with classical carcinoid
- Tumors of low malignant potential
- Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option.
- Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces.
- Women who are pregnant or lactating.
- Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
- Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
- Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology.
- Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent.
- New York Heart Association (NYHA) Class II or higher Congestive heart failure.
- Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
- Patients with known floxuridine, leucovorin ,or mitomycin allergy.
- Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
- Any condition that would preclude the ability to deliver appropriate IP therapy.
- Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
- Life expectancy < 12 weeks.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Appendiceal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Experimental: Appendiceal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Experimental: Colorectal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Experimental: Colorectal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
disease-free survival
Prazo: 3 years
|
Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician. |
3 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
surgical toxicity grade 3 to 5
Prazo: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 |
up to 60 days
|
|
chemotherapy toxicity grade 3 to 5
Prazo: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities. |
up to 60 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Garrett Nash, MD, MPH, Memorial Sloan Kettering Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Neoplasias cecais
- Doenças cecais
- Neoplasias Colorretais
- Neoplasias do Apêndice
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Terapêutica
- Procedimentos cirúrgicos, operatórios
- Terapia medicamentosa
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Enzimas e coenzimas
- Indoles
- Nucleosídeos de pirimidina
- Pirimidinas
- Nucleosídeos
- Formiltetra -hidrofolatos
- Tetra -hidrofolatos
- Ácido fólico
- Pterins
- Pteridinas
- Hipertermia, induzida
- Coenzimas
- Quinonas
- Azirines
- Desoxirribonucleosídeos
- Terapia de modalidade combinada
- Desoxiuridina
- Uridina
- Mitomicinas
- Indolequinonas
- Quimioterapia, adjuvante
- Leucovorina
- Mitomicina
- Floxuridina
- Procedimentos cirúrgicos da citedução
- Quimioterapia intraperitoneal hipertermica
Outros números de identificação do estudo
- 12-289
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .